Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease

Recent epidemiological studies have established an association between the common consumption of coffee or other caffeinated beverages and a reduced risk of developing Parkinson's disease (PD). To explore the possibility that caffeine helps prevent the dopaminergic deficits characteristic of PD, we investigated the effects of caffeine and the adenosine receptor subtypes through which it may act in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin model of PD. Caffeine, at doses comparable to those of typical human exposure, attenuated MPTP-induced loss of striatal dopamine and dopamine transporter binding sites. The effects of caffeine were mimicked by several A(2A) antagonists (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH 58261), 3,7-dimethyl-1-propargylxanthine, and (E)-1,3-diethyl-8 (KW-6002)-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione) (KW-6002) and by genetic inactivation of the A(2A) receptor, but not by A(1) receptor blockade with 8-cyclopentyl-1,3-dipropylxanthine, suggesting that caffeine attenuates MPTP toxicity by A(2A) receptor blockade. These data establish a potential neural basis for the inverse association of caffeine with the development of PD, and they enhance the potential of A(2A) antagonists as a novel treatment for this neurodegenerative disease.

[1]  E. Ongini,et al.  Adenosine A2A Receptors and Neuroprotection , 1997, Annals of the New York Academy of Sciences.

[2]  M. Fernstrom,et al.  Effects of Caffeine on Monoamine Neurotransmitters in the Central and Peripheral Nervous System , 1984 .

[3]  K. Jacobson,et al.  Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells , 1998, FEBS letters.

[4]  Phillis Jw,et al.  Adenosine in the control of the cerebral circulation. , 1989 .

[5]  E. Ongini,et al.  Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats , 1998, Neuroreport.

[6]  L. Grégoire,et al.  Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys , 1999, Neurology.

[7]  B. Fredholm,et al.  Pharmacology of adenosine A2A receptors. , 1996, Trends in pharmacological sciences.

[8]  P. Svenningsson,et al.  Distribution, biochemistry and function of striatal adenosine A2A receptors , 1999, Progress in Neurobiology.

[9]  S. Schiffmann,et al.  Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor , 1997, Nature.

[10]  D. Deleu.  Smoking, alcohol, and coffee consumption preceding Parkinson’s disease , 2001, Neurology.

[11]  B. Fredholm,et al.  Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. , 1999, Pharmacological reviews.

[12]  P. Jenner,et al.  Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys , 1998, Annals of neurology.

[13]  J. Phillis.  Adenosine in the control of the cerebral circulation. , 1989, Cerebrovascular and brain metabolism reviews.

[14]  R. Mayfield,et al.  Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: Evidence for an A2a/D2 receptor interaction in globus pallidus , 1996, Synapse.

[15]  O. Steward,et al.  Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Benabid,et al.  Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies , 1996, The European journal of neuroscience.

[17]  C. Tanner,et al.  Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.

[18]  P. Jenner,et al.  Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. , 1997, Trends in pharmacological sciences.

[19]  T. Stone,et al.  Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist , 1998, Brain Research.

[20]  W. Willett,et al.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women , 2001, Annals of neurology.

[21]  G. Siegel,et al.  Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain , 2000, Brain Research Reviews.

[22]  M. Mouradian,et al.  Protection Against Acute MPTP‐Induced Dopamine Depletion in Mice by Adenosine A1 Agonist , 1993, Journal of neurochemistry.

[23]  P. Popoli,et al.  Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. , 1995, European journal of pharmacology.

[24]  J. Obeso,et al.  Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.

[25]  J. Ribeiro,et al.  Adenosine A2 receptor-mediated excitatory actions on the nervous system , 1996, Progress in Neurobiology.

[26]  P. Sonsalla,et al.  Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. , 1991, The Journal of pharmacology and experimental therapeutics.

[27]  A. Kupsch,et al.  Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. , 1995, Neuroreport.

[28]  Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. , 1994, The Journal of pharmacology and experimental therapeutics.

[29]  Hiroshi Kase,et al.  Adenosine A2A antagonists with potent anti-cataleptic activity , 1997 .

[30]  H. Kase,et al.  Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. , 1993, Journal of medicinal chemistry.

[31]  M. Moskowitz,et al.  A2A Adenosine Receptor Deficiency Attenuates Brain Injury Induced by Transient Focal Ischemia in Mice , 1999, The Journal of Neuroscience.